Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GH Research PLC - Ordinary Shares (NQ:GHRS)

14.70 -0.31 (-2.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about GH Research PLC - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price ↗
With the 82.6% collapse of Seelos Therapeutics (SEEL) last week, the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index declined by 13.0%, on average, and... 
Via Talk Markets
News headline image
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More ↗
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next 
Via Benzinga
News headline image
4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week ↗
4 of the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index were up in price last week versus only 1 the previous week. The Index was up 2.4% for the week... 
Via Talk Markets
News headline image
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More ↗
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
Via Benzinga
Topics Artificial Intelligence
News headline image
GH Research: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
6 Largest Psychedelic Compound-Based R & D Stocks In Decline ↗
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD. 
Via Talk Markets
News headline image
6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week ↗
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD. 
Via Talk Markets
News headline image
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More ↗
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety 
Via Benzinga
News headline image
August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15% ↗
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 15.0%, on average, in August and are now only up 5.3% YTD. 
Via Talk Markets
News headline image
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More ↗
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials 
Via Benzinga
News headline image
GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026 ↗
GH Research PLC (NASDAQ: GHRS), a clinical-stage biopharma company developing novel mebufotenin (5-MeO-DMT) therapies for Treatment-Resistant Depression (TRD) and one of the highest trading... 
Via Benzinga
News headline image
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports ↗
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds 
Via Benzinga
Topics Cannabis Economy
News headline image
Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend ↗
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in... 
Via Talk Markets
News headline image
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
News headline image
So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index ↗
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD. 
Via Talk Markets
News headline image
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances... 
Via Benzinga
News headline image
July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average ↗
All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July: 
Via Talk Markets
News headline image
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial ↗
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023: 
Via Benzinga
News headline image
Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD ↗
The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug... 
Via Talk Markets
News headline image
Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD ↗
Our Psychedelic Drug Stocks Index is up 12.3% MTD and is now up 25.1% YTD. 
Via Talk Markets
News headline image
Psychedelic Stocks Jumped 10% Last Week ↗
The FDA released a positive draft guidance for developing psychedelic treatments and the 6 largest stocks in the Psychedelic Drug Stocks Index responded accordingly 
Via Talk Markets
News headline image
Upward Trend In Largest Psychedelic Compound-Based R&D Stocks Continues ↗
Our Psychedelic Drug Stocks Index, which consists of the 6 largest psychedelic compound-based research & development companies, was up 3.4% this week, up 7.1% in June, up 6.3% in May, and is now up... 
Via Talk Markets
News headline image
The 3 Best Psychedelic Stocks to Buy Now ↗
Psychedelic stocks promise to bring therapeutics to market that were taboo until recently and have huge upside. 
Via InvestorPlace
News headline image
Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue ↗
There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD. 
Via Talk Markets
News headline image
Major Psychedelic Compound-Based Research & Development Stocks: June Update ↗
Psychedelic Drug Stocks Index has been revamped with the removal of Cybin (CYBN) which has dropped below $100M in market capitalization leaving 6 constituents in the Index 
Via Talk Markets
News headline image
May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances ↗
Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May. 
Via Talk Markets
News headline image
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More ↗
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... 
Via Benzinga
News headline image
Arlo Technologies, Array Technologies, AirSculpt Technologies And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded slightly lower, with the Dow Jones dropping around 15 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer ↗
GH Research PLC (NASDAQ: GHRS), a Dublin-based clinical-stage biotech company reported financial results for the first quarter ended March 31, 2023. 
Via Benzinga
News headline image
April Psychedelic Drug Stocks Recap: The Ups And Downs ↗
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.